Taysha Gene Therapies, Inc. (TSHA)

Price & Market Data

Price: $5.51

Daily Change: -$0.03 / 0.54%

Daily Range: $5.42 - $5.75

Market Cap: $1,577,611,904

Daily Volume: 1,656,371

Performance Metrics

1 Week: -11.77%

1 Month: -14.54%

3 Months: 14.42%

6 Months: 36.22%

1 Year: 91.37%

YTD: -1.36%

About Taysha Gene Therapies, Inc. (TSHA)

Essential market details for Taysha Gene Therapies, Inc. (TSHA). Current price: 5.51, daily change: -$0.03 / 0.54%. Market cap: 1,577,611,904. Dive into YTD, 1-week, and 6-month performance.

Company Details

Employees: 99

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Selected stocks

Veru Inc. (VERU)

Singularity Future Technology Ltd. (SGLY)

Cherry Hill Mortgage Investment Corporation (CHMI)

Fractyl Health, Inc. (GUTS)

Tenon Medical, Inc. (TNON)